March 2, 2015
Otsuka Pharmaceutical Co., Ltd.
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
Otsuka Pharmaceutical Co., Ltd. and the U.S.-based company Bristol-Myers Squibb have agreed to end the co-promotion arrangements for the drug SPRYCEL® (generic name: dasatinib) in Japan, effective from February 27, 2015.
Otsuka and Bristol-Myers Squibb established a global contract in April 2009 in the area of hematological cancers and have been co-promoting SPRYCEL® for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in Japan since January 2011. Bristol-Myers K.K. continues to promote SPRYCEL® in Japan
Otsuka Pharmaceutical will continue to receive a specified collaboration fee for SPRYCEL net sales in the U.S., Europe*, and Japan. There will be no decrease or other change in terms for the collaboration fee Otsuka Pharmaceutical receives as a result of the termination of co-promotion in Japan.
This change to the agreement is specific to Japan and independent of Bristol-Myers Squibb's partnership with Otsuka in the U.S. and Europe.
- Europe: 5 countries consisting of France, Germany, Italy, Spain and the U.K.
Information in this news release was current as of the original release date.